Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on December 18, 2017. The report details amendments to the company's credit facilities and securitization arrangements. The filing does not cover a specific financial reporting period but addresses specific legal and financial covenant adjustments effective as of the filing date.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, or liquidity metrics for a specific period. However, it references specific reserve amounts impacting debt covenants:
- Reserve for USAO-EDNY Civil Claims: $625.0 million (taken in the quarter ended September 30, 2017).
- Reserve for Plea Agreement Payment: $260.0 million (taken in the quarter ended June 30, 2017).
Material Changes
The primary material change is the execution of Amendment No. 1 to the company's Credit Agreements (Revolving Credit Facility, PharMEDium Term Loan, and MWI Term Loan) and amendments to its Receivables Purchase Agreement. These amendments modify the definition of "Consolidated EBITDA" to exclude the aforementioned $625.0 million and $260.0 million reserves. This adjustment ensures these specific legal settlements do not negatively impact the company's compliance with financial covenants.
Outlook, Risks, and Contingencies
Legal Contingencies: The filing confirms the existence of two significant legal matters resolved via agreements with the United States Attorney's Office for the Eastern District of New York (USAO-EDNY):
- A civil claim under the Federal False Claims Act (associated with the $625.0 million reserve).
- A misdemeanor violation of the Federal Food, Drug, and Cosmetic Act (associated with the $260.0 million payment).
Lender Relationships: The filing discloses that various lenders and their affiliates (including Citigroup, J.P. Morgan, Bank of America, Mitsubishi UFJ, and Wells Fargo) provide investment banking, commercial banking, and advisory services to the company, creating potential conflicts of interest typical in such arrangements.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 to the Credit Agreements in the upcoming Form 10-Q for the quarter ending December 31, 2017.
- Review the Form 10-K for the fiscal year ended September 30, 2017, for detailed descriptions of the USAO-EDNY settlements.
- Confirm the impact of the EBITDA definition change on the company's leverage ratios and covenant compliance status.
- Monitor future filings for any additional payments or legal developments related to the disclosed False Claims Act and Food, Drug, and Cosmetic Act matters.